GlassScriptPhysician profile
Aqil Pesh Imam
NPI 1730173212
$6,900.50
in general payments reported to CMS, 2019-2025
23 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $238 · 2021: $755 · 2022: $1,262 · 2023: $1,363 · 2024: $970 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,316.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,058.25 | 2019-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $827.17 | 2019-2025 | |
| Genentech USA, INC. | $569.81 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $444.83 | 2021-2025 | Orladeyo |
| Csl Behring | $353.98 | 2019-2025 | Haegarda, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.94 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.01 | 2020-2024 | Takhzyro |
| Merck Sharp & Dohme LLC | $301.23 | 2019-2023 | |
| Optinose US, INC. | $279.35 | 2019-2025 | |
| Pfizer INC. | $239.24 | 2019-2024 | |
| Ionis Pharmaceuticals, INC. | $216.11 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $170.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.32 | 2023-2025 | Dupixent |
| Phadia US INC. | $80.26 | 2019-2024 | Immunocap |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $63.06 | 2023-2024 | Quzyttir |
| Adma Biomanufacturing LLC | $55.49 | 2024 | |
| Genentech, INC. | $34.62 | 2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $28.20 | 2025 | Neffy |
| Octapharma USA, INC. | $25.50 | 2024 | Octagam Immune Globulin (Human) |
| Amgen INC. | $23.06 | 2024 | Tezspire |
| Galderma Laboratories, L.P. | $17.77 | 2025 | Nemluvio |
| Shire North American Group INC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aqil Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.